Duchenne Muscular Dystrophy (DMD) Drugs Market Analysis, Status and Business Outlook 2021 to 2028 | Sarepta, PTC, Santhera, Italfarmaco, and Catabasis

Global Duchenne Muscular Dystrophy (DMD) Drugs Market to Grow due to Increasing Focus on Improving Healthcare

Duchenne muscular dystrophy (DMD) therapeutics help treat this genetic disorder caused by the absence of dystrophin, a protein found in the human body. Duchenne muscular dystrophy (DMD) is a genetic disorder characterized by the progressive degeneration of muscles and their weakness. It is a rare muscle disease that largely affects men. An increase in the number of patients with Duchenne muscular dystrophy is expected to propel the global Duchenne muscular dystrophy treatment market during the forecast period. According to the National Organization for Rare Disorders, one in 3,500 male babies born worldwide is affected with Duchenne muscular dystrophy. Overall, muscular dystrophies affect 250,000 individuals in the U.S.

Key Factors Impacting the Global Duchenne Muscular Dystrophy (DMD) Drugs Market:

1. The exon skipping segment accounted for a major share of the global Duchenne muscular dystrophy treatment market. The segment is expected to continue its dominance in the next few years due to the majority of exon skipping drugs undergoing Phase-3 clinical trials. Only one drug approved for Duchenne muscular dystrophy, Exondy 51, falls under the exon skipping therapeutics.
2. Increasing treatment options for underserved categories, such as infants and nonambulant patients, are estimated to augur well for the market in the foreseeable future.
3. Extensive research and development efforts are expected to offer new opportunities in the market.

Companies Seeking Product Approval and Aiming to Expand Product Portfolio

As per the recent trends, companies having various strategic collaborations and the growing support provided by government and healthcare agencies are expected to have a synergistic effect on market. Such developments lead to partnership and boost the market competition. The companies are also developing new products and seeking FDA Approvals.

• December 12, 2019 – The U.S. Food and Drug Administration approved Vyondys 53 (golodirsen) injection for a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping, to treat Duchenne muscular dystrophy (DMD) patients.

U.S. to Become the Largest Market due to Increasing R&D Activities

The U.S. is expected to continue leading the market until 2023. Booming treatment rate, High incidence of DMD in the U.S., and anticipated launch of pipeline products are some of the factors that are propelling the market in the country.

China, Japan, India, South Korea, and Australia are amongst some of the key countries for the global market in the region. Other regions including the Middle East, Eastern Europe, and Rest of the World (South America and Africa) are estimated to be emerging markets during the forecast period.

Available Exclusive Sample Copy of this Report at https://www.quincemarketinsights.com/request-sample-68374?utm_source=SK&utm_medium=OPENPR&utm_campaign=SK

This Global Duchenne Muscular Dystrophy (DMD) Drugs Market Report Provides:
1. An overview of thorough analysis of the global marketand related technologies.
2. Study of the latest trends with precise annual growth rate estimates for compounds (CAGRs) and yearly valuations.
3. Identification of new market opportunities and targeted consumer marketing strategies for global market.
4. Demand for new applications with new technologies and breakdown
5. Wide-ranging company profiles of significant players in industry.

The report offered by our experts presents in exhaustive market study with have established segments such as application, product type, and region. Every segment of the market and its sub-segments are comprehensively and are based on their growth scenarios, market share, and CAGR. In each market segment qualitative and quantitative information is offered with in-depth information for offering a complete market outlook.
Major companies functioning in market are Sarepta, PTC, Santhera, Italfarmaco, and Catabasis.

Market Segmentation:
By Therapeutic Approach:
• Mutation Suppression
• Exon Skipping
• Steroid Therapy

By Region:

North America Duchenne Muscular Dystrophy (DMD) Drugs Market
• North America, by Country
o US
o Canada
o Mexico
• North America, by Therapeutic Approach

Europe Duchenne Muscular Dystrophy (DMD) Drugs Market
• Europe, by Country
o Germany
o Russia
o UK
o France
o Italy
o Spain
o The Netherlands
o Rest of Europe
• Europe, by Therapeutic Approach

Asia Pacific Duchenne Muscular Dystrophy (DMD) Drugs Market
• Asia Pacific, by Country
o China
o India
o Japan
o South Korea
o Australia
o Indonesia
o Rest of Asia Pacific
• Asia Pacific, by Therapeutic Approach

Middle East & Africa Duchenne Muscular Dystrophy (DMD) Drugs Market
• Middle East & Africa, by Country
o UAE
o Saudi Arabia
o Qatar
o South Africa
o Rest of Middle East & Africa
• Middle East & Africa, by Therapeutic Approach

South America Duchenne Muscular Dystrophy (DMD) Drugs Market
• South America, by Country
o Brazil
o Argentina
o Colombia
o Rest of South America
• South America, by Therapeutic Approach

Objectives of this report:
• To estimate market size for duchenne muscular dystrophy (DMD) drugs market on regional and global basis.
• To identify major segments in duchenne muscular dystrophy (DMD) drugs market and evaluate their market shares and demand.
• To provide a competitive scenario for the duchenne muscular dystrophy (DMD) drugs market with major developments observed by key companies in the historic years.
• To evaluate key factors governing the dynamics of duchenne muscular dystrophy (DMD) drugs market with their potential gravity during the forecast period.

Customization:
This study is customized to meet your specific requirements:
• By Segment
• By Sub-segment
• By Region/Country
• Product Specific Competitive Analysis

Contact:
Quince Market Insights
Office No- A109
Pune, Maharashtra 411028
Phone: APAC +91 706 672 4848 / US +1 208 405 2835 / UK +44 121 364 6144
Email: sales@quincemarketinsights.com
Web: www.quincemarketinsights.com

ABOUT US:
QMI has the most comprehensive collection of market research products and services available on the web. We deliver reports from virtually all major publications and refresh our list regularly to provide you with immediate online access to the world's most extensive and up-to-date archive of professional insights into global markets, companies, goods, and patterns.

This release was published on openPR.